FDA approves neratinib for extended adjuvant treatment of early stage HER2-positive breast cancer. On July 17, 2017, the U.S. Food and Drug Administration approved neratinib (NERLYNX, Puma Biotechnology, Inc.) for the extended adjuvant treatment of adult patients with early stage HER2- verexpressed / amplified breast cancer, to follow adjuvant trastuzumab-based therapy.
Are you looking for or in search of FDA approved “neratinib tablets in India”? “Medicant Healthcare” a registered pharmacy firm in India deals in both brand name as well as generic name Drugs / medicine approved for Breast Cancer. Need Access of neratinib tablets, get in touch with our healthcare professional.
INDICATIONS AND USAGE
NERLYNX is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.
DOSAGE FORMS AND STRENGTHS
Tablets: 40 mg.